Free Trial
TSE:ASP

Acerus Pharmaceuticals (ASP) Stock Price, News & Analysis

Acerus Pharmaceuticals logo

About Acerus Pharmaceuticals Stock (TSE:ASP)

Advanced Chart

Key Stats

Today's Range
N/A
50-Day Range
N/A
52-Week Range
N/A
Volume
1,250 shs
Average Volume
4,719 shs
Market Capitalization
C$2.78 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Acerus Pharmaceuticals Corporation, a specialty pharmaceutical company, focuses on the development, manufacture, marketing, and distribution of pharmaceutical products for men's and women's health. The company offers Natesto, a nasal gel for testosterone replacement therapy in adult males diagnosed with hypogonadism; and Noctiva, a vasopressin analog indicated for the treatment of nocturia due to nocturnal polyuria in adults who awaken at least 2 times per night to void. It also engages in developing Lidbree, a short acting lidocaine formulation delivered through a proprietary device into the vaginal mucosal tissue; Stendra, a PDE5 inhibitor for the treatment of erectile dysfunction; Tefina, a clinical stage product for women with female sexual dysfunction; and Noctiva combination products, which are in the pre-clinical development stage for the treatment of benign prostatic hypertrophy, overactive bladder, and pediatric nocturnal enuresis. In addition, the company provides TriVair technology platform for pulmonary and nasal dosing. It sells its products through its salesforce in the United States and Canada; and through a network of distributors internationally. The company was formerly known as Trimel Pharmaceuticals Corporation and changed its name to Acerus Pharmaceuticals Corporation in September 2015. Acerus Pharmaceuticals Corporation was founded in 2008 and is headquartered in Mississauga, Canada.

Receive ASP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Acerus Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

ASP Stock News Headlines

Acerus Update
“You all just got a lot richer”
Trump Knows What He’s Doing. When the president says he’s going to let RFK “go wild” … and Big Pharma crashes. Do you think that’s an accident? When he threatens to “End the Fed” do you think he doesn’t know banking stocks will benefit? What about when he tells his followers, “Now is a good time to buy,” hours before relaxing tariffs and sending the market soaring? Is that an accident? Larry Benedict doesn’t think so. He thinks Trump knows what he’s doing… and believes he’s found the perfect tickers for everyday Americans to take advantage next time he triggers a big move.
IIROC Trading Halt - ASP
Acerus Files For CCAA Protection
Acerus: Q3 Earnings Snapshot
See More Headlines

ASP Stock Analysis - Frequently Asked Questions

Shares of ASP stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.

Based on aggregate information from My MarketBeat watchlists, some other companies that Acerus Pharmaceuticals investors own include Aurora Cannabis (ACB), Surna (SRNA), Allena Pharmaceuticals (ALNA), Molecular Templates (MTEM), Absolute Software Co. (ABT.TO) (ABT), Achieve Life Sciences (ACHV) and Algonquin Power & Utilities (AQN).

Industry, Sector and Symbol

Stock Exchange
TSE
Sector
Medical
Industry
Drug Manufacturers - Specialty & Generic
Sub-Industry
N/A
Current Symbol
TSE:ASP
CIK
N/A
Fax
N/A
Employees
14
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-C$28.08 million
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
C$3.04 million
Price / Cash Flow
3.29
Book Value
C($1.80) per share
Price / Book
N/A

Miscellaneous

Free Float
N/A
Market Cap
C$2.78 million
Optionable
Not Optionable
Beta
1.03
The Best High-Yield Dividend Stocks for 2025 Cover

Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

This page (TSE:ASP) was last updated on 5/28/2025 by MarketBeat.com Staff
From Our Partners